NCT03466411: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 1,409 taking part
- Started
- 13 Apr 2018
- Primary completion
- 20 Oct 2023
- Arms
- Phase 2 (GALAXI 1): Group 1 (Guselkumab), Phase 2 (GALAXI 1): Group 2 (Guselkumab), Phase 2 (GALAXI 1): Group 3 (Guselkumab), Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)
- Results
- Posted on the registry
- 15 Mar 2018: Trial registered
- 13 Apr 2018: Trial started
- 7 May 2025: Trial results posted